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1 |  INTRODUCTION
Retinal vein thrombosis is the second most common cause 
of vision loss after diabetic retinopathy.1 Risk factors include 
atherosclerosis, advanced age, hypertension, diabetes, and 
hyperlipidemia,1-4 which also increase the propensity for 
deep venous thromboembolism and pulmonary embolism.
Cancer induces a systemic pro‐coagulant state, which in-
creases the risk of venous thromboembolism.5,6 Thus, venous 
thromboembolism in the lower extremities and the lungs are 
markers of cancer.7-13 Several case reports have suggested 
that retinal vein thrombosis may also be a clinical sign of 
cancer, especially hematological cancers,2,3,10,14-17 but firm 
epidemiological evidence is lacking. Putative mechanisms 
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Abstract
Background: Retinal vein thrombosis has in case reports been reported a clinical 
sign of cancer, especially hematological cancer. However, it is unclear whether reti-
nal vein thrombosis is a marker of underlying cancer, as is the case for deep venous 
thrombosis and pulmonary embolism. We investigated the risk of occult cancer in 
patients with retinal vein thrombosis.
Methods: A nationwide population‐based cohort study in Denmark on all patients diag-
nosed with a retinal vein thrombosis during 1994 and 2013. The main outcome measures 
were any cancer and site‐specific cancers <6 months, 6‐12 months, and 5 years following 
a retinal vein thrombosis diagnosis, as registered in the Danish Cancer Registry and the 
National Pathology Registry. We calculated the absolute cancer risk and computed stand-
ardized incidence ratios (SIRs) with 95% confidence intervals (CIs) for cancer within 
<6 months, 6‐12 months, and 5 years following a retinal vein thrombosis diagnosis.
Results: Among 9589 patients with retinal vein thrombosis, we observed 1514 cancer 
cases. The risk of any cancer was 1.2% <6 months and 28.8% after 5 years. The <6 months 
SIR was 1.20 (95% CI 0.99‐1.44), 6‐12 months SIR was 1.15 (95% CI 0.94‐1.39), and the 
5 years’ SIR was 1.08 (95% CI 1.03‐1.14). Stratification by age, gender, calendar year, 
and Charlson Comorbidity Index score did not change overall cancer risk estimates.
Conclusion: Retinal vein thrombosis was not an important clinical marker for occult 
cancer. An extensive diagnostic cancer workup does not appear warranted for retinal 
vein thrombosis patients.
K E Y W O R D S
cohort study, neoplasm, retinal vein occlusion, risk, venous thromboembolism
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involve direct neoplastic infiltration leading to impaired 
drainage and obstruction of the retinal veins, as well as de-
hydration and hyperviscosity caused by the cancer.1-3,16,18 To 
investigate these suppositions, we examined the risk of can-
cer following a retinal vein thrombosis compared with cancer 
risk in the general population.
2 |  METHODS
2.1 | Setting
Denmark has a tax‐supported health care system ensuring 
equal and income‐independent free access to health care 
services for all residents. Individuals born in or immigrat-
ing to Denmark receive a unique Civil Personal Registration 
Number, enabling accurate linkage among Danish regis-
tries at the individual level.19 In the present study, we used 
data from the Danish National Patient Registry (DNPR),20 
the Danish Cancer Registry (DCR),21,22 and the Civil 
Registration System (CRS).19 The DNPR has recorded 
data on all admissions and discharges from non‐psychiatric 
hospitals since 1977 and from emergency rooms and out-
patient clinics since 1995.20 Each hospital discharge or out-
patient visit has been coded according to the International 
Classification of Diseases, Eighth Revision (ICD‐8) from 
1977 until the end of 1993 and the Tenth Revision (ICD‐10) 
thereafter. The DCR contains complete prospectively col-
lected data on all incident cases of primary cancer diag-
nosed in Denmark since 1943.21-23 DCR data include 
information on tumor staging according to TNM and Ann 
Arbor classifications.22 Reporting to the DCR has been 
mandatory for all hospital departments since 1987 and 
for general practitioners since 2004, ensuring nationwide 
completeness of its data.21-2321-23 DCR data are linked to 
the National Pathology Registry, ensuring high validity of 
cancer diagnoses; 89% of diagnoses in the DCR have his-
topathological verification.24 The high quality of DCR data 
also is ensured by continuous manual and electronic qual-
ity control.
T A B L E  1  Diagnosis codes for study exposures, outcomes, and covariates according to the International Classification of Diseases, Eighth 
and Tenth Revisions (ICD‐8 and ICD‐10)
ICD‐8 codes ICD‐10 codes
Exposure
Retinal vein thrombosis 377.08 DH348
Outcome
Cancer 140‐209 C00‐C99
Covariates
Diabetes 24900, 24906, 24907, 24909, 25000, 25006, 
25007, 25009
E10‐E14 (except E102, E112, E142). O24 (except O24.4), 
G63.2, H36.0, N08.3
Atrial fibrillation or atrial 
flutter
42793, 42794 I48
Myocardial infarction 410 I21
Heart failure 42709, 42710, 42711, 42719, 42899, 78249 I50.0, I50.1, I50.2, I50.3, I50.8, I50.9, I11.0, I13.0, I13.2, 
I42.0, I42.7, I42.8, I42.9
Lower‐extremity deep 
venous thrombosis or 
pulmonary embolism
45100, 45099 I80.1‐3, I26
Chronic renal disease 249.02, 250.02, 753.10‐753.19, 582, 583, 584, 
590.09, 593.20, 792
E10.2, E11.2, E14.2, N03, N05, N11.0, N14; N16, 
N18‐N19, N26.9, Q61.1‐Q61.4
Chronic pulmonary disease 490‐493; 515‐518 J40‐J47; J60‐J67; J68.4; J70.1; J70.3; J84.1; J92.0; J96.1; 
J98.2; J98.3
Obesity 277 E65‐E68
Alcoholism‐related 
disorders
980, 291.09‐291.99, 303.09‐303.99, 57109‐57111, 
57710
F10 (except F10.0), G31.2, G62.1, G72.1, I42.6, K29.2, 
K86.0, Z72.1
Risk factors for venous thromboembolism
Fracture/trauma 800‐929, 950‐959 S00‐T14
Surgery N/A Previous Danish classification until 1996:000000‐99960; 
NOMESCO classification after 1996: KA‐KQ, KX, KY
Pregnancy 630‐680 O00‐O99
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2.2 | Study population
We used the DNPR and DCR to identify all patients diag-
nosed with retinal vein thrombosis, on an inpatient or hospital 
outpatient basis, between 1 January 1994 and 30 November 
2013. A history of a previous cancer diagnosis was an ex-
clusion criteria. We defined date of discharge or outpatient 
contact as the retinal vein thrombosis diagnosis date. We ob-
tained information from the DNPR on comorbid conditions, 
including a history of deep venous thrombosis, myocardial 
infarction, heart failure, atrial fibrillation or flutter, chronic 
pulmonary disease, chronic kidney disease, diabetes melli-
tus, obesity, and alcoholism‐related disorders, as well as pro-
voking factors for deep venous thrombosis within 90 days of 
the retinal vein thrombosis event (fracture, trauma, surgery, 
pregnancy). We used the Charlson Comorbidity Index to 
categorize patients’ comorbidity burden at the time of retinal 
vein thrombosis (normal: score = 0; moderate: score = 1 or 
2; or severe: score ≥ 3).25,26
2.3 | Cancer incidence
The primary outcome was the absolute risk of all cancers re-
corded in the DCR. We obtained data on tumor staging at the 
time of diagnosis for all cancer cases according to the TNM 
classification and Ann Arbor classification.22,23
2.4 | Statistical analyses
We followed patients from the date of retinal vein thrombo-
sis diagnosis until a diagnosis of cancer recorded in the DCR, 
death, emigration, or end of the study period (30 November 
All retinal vein 
thrombosis patients 0‐50 y 50+ y
N (%) N (%) N (%)
Total 9589 (100.0) 894 (100.0) 8695 (100.0)
Male sex 4714 (49.2) 495 (55.4) 4219 (48.5)
Calendar year of diagnosis
1994‐2001 3411 (35.6) 299 (33.4) 3112 (35.8)
2002‐2009 3801 (39.6) 363 (40.6) 3438 (39.5)
2010‐2013 2377 (24.8) 232 (26.0) 2145 (24.7)
CCI comorbidity score
Normal 6050 (63.1) 722 (80.8) 5328 (61.3)
Moderate 2868 (29.9) 149 (16.7) 2719 (31.3)
Severe 671 (7.0) 23 (2.6) 648 (7.5)
Medical history
Myocardial infarction 552 (5.8) 11 (1.2) 541 (6.2)
Heart failure 460 (4.8) 9 (1.0) 451 (5.2)
Lower‐extremity deep 
venous thrombosis or 
pulmonary embolism
230 (2.4) 13 (1.5) 217 (2.5)
Atrial fibrillation or atrial 
flutter
668 (7.0) 11 (1.2) 657 (7.6)
Chronic kidney disease 217 (2.3) 25 (2.8) 192 (2.2)
Chronic pulmonary disease 725 (7.6) 25 (2.8) 700 (8.1)
Diabetes mellitus 973 (10.1) 69 (7.7) 904 (10.4)
Obesity 322 (3.4) 39 (4.4) 283 (3.3)
Alcoholism‐related 
disorders
189 (2.0) 30 (3.4) 159 (1.8)
Pregnancy within 90 d 7 (0.1) 7 (0.8) 0 (0)
Surgery within 90 d 3093 (32.3) 159 (17.8) 2934 (33.7)
Fracture/trauma within 90 d 253 (2.6) 22 (2.5) 231 (2.7)
CCI, Charlson Comorbidity Index.
Normal (score = 0), moderate (score = 1‐2), or severe (score ≥ 3),
T A B L E  2  Characteristics of retinal 
vein thrombosis patients according to age at 
diagnosis, Denmark, 1997‐2013
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2013), whichever came first. We tabulated patient character-
istics as described above, and for improving specificity, we 
calculated the proportion of patients diagnosed with retinal 
vein thrombosis at hospital departments of ophthalmology. We 
calculated absolute cancer risks using the cumulative incidence 
risk function, accounting for death as a competing risk.27 As a 
measure of relative risks, we furthermore calculated standard-
ized incidence ratios (SIRs) for cancer, using indirect stand-
ardization, as the ratio of the observed number of cancer cases 
to the number of cancer cases expected in the general popula-
tion among persons of the same age and in the same calen-
dar period (in one‐year intervals) based on data in the DCR.28 
We investigated the risk of cancer overall, within <6 months, 
6‐12 months, and more than one year following the retinal vein 
thrombosis diagnosis. Analyses were stratified by age, gender, 
calendar year, and comorbidity burden according to Charlson 
comorbidity scores.25,26 Assuming that cancers diagnosed 
during the first year of follow‐up were present at the time of 
retinal vein thrombosis diagnosis, we computed the number of 
patients needed to screen at the time of diagnosis in order to 
detect one excess cancer as the reciprocal of the excess risk.
ICD codes used in the study are provided in Table 1. All 
statistical analyses were performed using SAS version 9.4 
(SAS Institute, Cary, NC).
The study was approved by the Danish Data Protection 
Agency (record number 1‐16‐02‐1‐08).
3 |  RESULTS
We followed 9589 patients diagnosed with a retinal vein 
thrombosis for a median of 5.1 years (25th–75th percen-
tile: 2.2‐9.2 years; Table 2). Median age at the retinal vein 
thrombosis event was 70 years with equal gender distribu-
tion. Approximately 90% of patients were older than age 
50 years when they experienced a retinal vein thrombosis. 
As expected, these patients had a higher comorbidity burden 
(including cardiovascular diseases) compared with patients 
aged below 50 years (Table 2). One‐third of the patients 
aged 50 years or more had undergone surgery within 90 days 
before the event. Nearly all retinal vein thrombosis patients 
(95%) were diagnosed at ophthalmologic departments.
F I G U R E  1  Overall and site‐specific cancer risk during entire follow‐up in patients with retinal vein thrombosis, Denmark, 1997‐2013, 
expressed as absolute numbers and standardized incidence rates (SIRs) with lower (LCL) upper confidence limits (UCL). Site‐specific cancers with 
at least three cases included in the figure
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Overall, we observed 1514 cancer events (Figure 1). During 
overall follow‐up, we observed a 20% increase in the risk of he-
matological cancer among patients with retinal vein thrombo-
sis (overall SIR 1.20, 95% CI 0.97‐1.48, data not shown). The 
<6‐month risk of any cancer was 1.2% (95% CI 1.0%‐1.5%), 
increasing to 2.4% (95% CI 2.1%‐2.7%) one year after retinal 
vein thrombosis, and 28.8% (95% CI 26.9%‐30.8%) >5 years 
(end of follow‐up). The <6 months’ SIR was 1.20 (95% CI 
0.99‐1.44; Figure 2) and remained unchanged 6‐12 months fol-
lowing retinal vein thrombosis (SIR 1.15, 95% CI 0.94‐1.39), 
>1 year after the event (SIR 1.07, 95% CI, 1.01‐1.13), and 
≥5 years after the event (SIR 1.08, 95% CI 1.03‐1.14).
Among patients with retinal vein thrombosis, 53% of can-
cers were localized tumors, 12% were tumors with regional 
spread, 15% were tumors with distant metastases, and 20% 
had missing data on tumor staging. The overall SIR estimates 
were almost similar in subgroups of patients, according to age, 
gender, calendar year, and comorbidity burden, measured by 
the Charlson comorbidity score (Figure 3). Based on 33 excess 
cancers detected during a follow‐up time of 8969 person‐years 
(corresponding to the first year of follow‐up), the number of 
patients with retinal vein thrombosis needed to screen to de-
tect one excess cancer per year was 271 for any cancer.
4 |  DISCUSSION
In this nationwide population‐based cohort study, the abso-
lute cancer risk within six months following a retinal vein 
thrombosis was low and only slightly increased compared to 
the general population. Thus, retinal vein thrombosis was not 
an important clinical marker for occult cancer. Interestingly, 
the relative cancer risk beyond the first year following reti-
nal vein thromboses was comparable with the cancer risk 
reported for deep venous thrombosis.8 This is probably ex-
plained by the comorbidity burden or common risk factors. 
Previous case reports suggesting an association between reti-
nal vein thrombosis and hematological cancers could not be 
confirmed.2,3,10,14-17
Although deep venous thrombosis and pulmonary embo-
lism are strong markers for occult cancer,7-9,11-13 this was not 
observed for retinal vein thrombosis. This suggests that different 
F I G U R E  2  Overall and site‐specific cancer risk during first 6 mo following a retinal vein thrombosis, Denmark, 1997‐2013, expressed as 
absolute numbers and standardized incidence rates (SIRs) with lower (LCL) and upper confidence limits (UCL). Site‐specific cancers with at least 
three cases included in the figure
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underlying mechanisms are likely to be involved in the patho-
physiology of venous thrombosis at different vascular sites. 
Disturbances in one or more of the components of the Virchow’s 
triad (stasis of blood flow, vessel wall injury, and hypercoagula-
bility) usually explain deep venous thrombosis and pulmonary 
embolism. Activation of the coagulation cascade, a systemic 
hypercoagulability, is essential for the venous clot formation 
observed in the larger veins11,13 and may be caused by cancer. 
In contrast, it seems likely that most cases of retinal vein throm-
bosis in our study were caused by shared risk factors for ath-
erosclerosis, for example, stiffness in adjacent arteriosclerotic 
arteries leading to turbulence and retinal thrombus formation.1-4 
This was supported by the high prevalence of arteriosclerosis 
we observed, especially in the older age groups. By contrast, the 
subgroup of young patients had a low comorbidity burden and, 
not surprisingly, had an increased cancer risk within the first 
year following a retinal vein thrombosis. Other etiologies may 
have played a role for their thrombosis, for example, underly-
ing cancer. Nevertheless, the estimates for this subgroup were 
based on few cancer cases with rather imprecise risk estimates. 
The present study was overall a negative study. Furthermore, 
we reported no P‐values and made no significance testing. 
Therefore, adjustments for multiple comparisons are not recom-
mended.29,30 However, in the present study on cancer risk with 
multiple comparisons, we cannot rule out by chance findings.
We based our study on prospectively collected nationwide 
data with complete population coverage in the setting of a uni-
versal tax‐supported health care system, which likely eliminated 
selection and recall bias. Confounding is generally not a prob-
lem in the reporting of absolute risks. As regards the relative 
SIR estimates, stratification by possible confounders did not 
substantially change the SIRs. The validity of the retinal vein 
thrombosis in the DNPR is assumed to be high, because nearly 
all retinal vein thrombosis patients were diagnosed at ophthal-
mologic departments. Nevertheless, we cannot rule out mis-
classification of some of the retinal vein thrombotic events. The 
validity of cancer diagnoses in the DCR is high.21-23
In conclusion, the absolute risk of occult cancer in retinal vein 
thrombosis was low, as reflected in the high number needed to 
screen. An extensive diagnostic cancer workup does not appear 
warranted for retinal vein thrombosis patients. The clinical impact 
of these negative findings is important. Furthermore, the results of 
F I G U R E  3  Overall cancer risk during entire follow‐up in patients with retinal vein thrombosis, Denmark, 1997‐2013, expressed as absolute 
numbers and standardized incidence rates (SIRs) with lower (LCL) upper confidence limits (UCL).Stratified on age and calendar year at retinal vein 
thrombosis, gender, and Charlson Comobidity Index (CCI)
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our study may contribute to our understanding of the mechanisms 
of carcinogenesis. The occult cancer‐associated hypercoagula-
bilty contributing to an increased risk of venous thromboembo-
lism does not seem to cause retinal vein thrombosis.11
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